tbuckley/cabot-search huggingface dataset:
Abstract 15702: Reperfusion Therapy With Rapamycin in Diabetic Heart: Essential Role of STAT3 Signaling
Authors: Anindita Das, Fadi N Salloum, David Durrant, Rakesh C Kukreja
Journal: Circulation (2014)

Background: Diabetic patients suffer augmented severity of myocardial infarction. Excessive activation of the mammalian target of rapamycin (mTOR) is implicated in diabetic complications and plays a critical role in myocardial reperfusion injury following ischemia. mTOR inhibition with rapamycin improves cardiac function in type 2 diabetic (T2D) heart. Since activated STAT3 is decreased in T2D heart, we hypothesized that reperfusion therapy with rapamycin would reduce myocardial infarct size in these hearts through STAT3 signaling. Methods and Results: Hearts from adult male db/db or wild type (WT) C57 mice were isolated and subjected to 30 min of ischemia and 60 min of reperfusion in Langendorff mode. Rapamycin (100 nM) was infused at the onset of reperfusion. Myocardial infarct size (IS) was significantly reduced in rapamycin-treated mice (13.3±2.4%) compared to DMSO control (36.2±1.3%) or WT mice (27.7±1.1%) (Fig. A). Rapamycin treatment restored phosphorylation of STAT3 and enhanced AKT phosphorylation (target of mTORC2), but significantly reduced ribosomal protein S6 phosphorylation (target of mTORC1) in heart (Fig. B). We further investigated the effect of rapamycin in high fat diet (HFD) fed inducible cardiac-specific STAT3-deficient (MCM TG:STAT3flox/flox) and WT mice (MCM TG:STAT3flox/flox). Rapamycin treatment during reperfusion significantly reduced IS in WT mice following I/R but not in STAT3-deficient mice (Fig. C). Rapamycin treatment during reoxygenation following 40 min of simulated ischemia also demonstrated resistance against necrosis (trypan blue staining) and apoptosis (TUNEL assay) in primary cardiomyocytes isolated from HFD-fed WT mice but not in cardiomyocytes from HFD-fed STAT3-deficient mice (Fig. D). Conclusion: STAT3 signaling plays a critical role in reducing myocardial infarct size and attenuating cardiomyocyte death following reperfusion therapy with rapamycin in T2D.
Long-Term Consequences of Kidney Donation
Authors: Connie L. Davis, Matthew Cooper
Journal: New England Journal of Medicine (2009)

BACKGROUND-The long-term renal consequences of kidney donation by a living donor are attracting increased appropriate interest.The overall evidence suggests that living kidney donors have survival similar to that of nondonors and that their risk of end-stage renal disease (ESRD) is not increased.Previous studies have included relatively small numbers of donors and a brief follow-up period.METHODS-We ascertained the vital status and lifetime risk of ESRD in 3698 kidney donors who donated kidneys during the period from 1963 through 2007; from 2003 through 2007, we also measured the glomerular filtration rate (GFR) and urinary albumin excretion and assessed the prevalence of hypertension, general health status, and quality of life in 255 donors. RESULTS-The survival of kidney donors was similar to that of controls who were matched for age, sex, and race or ethnic group.ESRD developed in 11 donors, a rate of 180 cases per million persons per year, as compared with a rate of 268 per million per year in the general population.At a mean (±SD) of 12.2±9.2years after donation, 85.5% of the subgroup of 255 donors had a GFR of 60 ml per minute per 1.73 m 2 of body-surface area or higher, 32.1% had hypertension, and 12.7% had albuminuria.Older age and higher body-mass index, but not a longer time since donation, were associated with both a GFR that was lower than 60 ml per minute per 1.73 m 2 and hypertension.A longer time since donation, however, was independently associated with albuminuria.Most donors had quality-of-life scores that were better than population norms, and the prevalence of coexisting conditions was similar to that among controls from the National Health and Nutrition Examination Survey (NHANES) who were matched for age, sex, race or ethnic group, and body-mass index.CONCLUSIONS-Survival and the risk of ESRD in carefully screened kidney donors appear to be similar to those in the general population.Most donors who were studied had a preserved GFR, normal albumin excretion, and an excellent quality of life.Kidney transplantation, particularly from a living donor, is the treatment of choice for most patients with end-stage renal disease (ESRD). 1 The superior results achieved with kidney transplantation from living donors have resulted in an increase in this method of transplantation. 2
Abstract Art in Five Tones and Complementaries
Authors: M. Therese Southgate
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Confidentiality and “Jambo, Jahi”
Authors: Andrea Lyman
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 11760: The Outcomes of Children Implanted With Ventricular Assist Devices in the US: First Analysis of the Pediatric Interagency Registry for Mechanical Circulatory Support (PediMACS)
Authors: Elizabeth D Blume, David N Rosenthal, Joseph W Rossano, J. T Baldwin, Pirooz Eghtesady, David L Morales, Ryan S Cantor, Jennifer Conway, Christopher S Almond, David C Naftel, James K Kirklin
Journal: Circulation (2014)

BACKGROUND: Use of pediatric mechanical circulatory support to decrease mortality has expanded dramatically. A national account of the use of FDA-approved devices in children is essential to understanding outcomes, refining patient selection, and improving quality of care. METHODS: PediMACs is an NIH-supported national registry for FDA-approved temporary and durable VAD usage in patients &lt; 18 years of age. Between the launch in Sept 2012 and March 2014, 32 US hospitals enrolled patients. This first report of data from this registry analyzed pre-implant patient characteristics, survival using competing outcomes, and adverse events. RESULTS: One hundred and thirty pediatric pts underwent 153 VAD implantations. Etiology of heart disease included 87 (67%) pts with cardiomyopathy, 26 (20%) with congenital heart disease. Twenty pts transitioned from ECMO and 37 had prior cardiac surgery. Most pts were Intermacs level 1 (28%) and level 2 (55%) at implant, with 12% Intermacs level 3. There were 26 temporary devices. Of the durable devices, 65 (51%) were pulsatile and 62 (49%) continuous flow (CF) (compared to adult Intermacs implants: 4% pulsatile, 96% CF). Age at first implant included 22 pts (17%) &lt; 1 yr of age, 23 (18%) 1-5 yrs, 26 (20%) 6-10 yrs and 59 (45%) 10-18 yrs. Patients were supported with LVAD alone in 99 (76%), BiVAD in 24 (18%) and total artificial heart in 2 (2%) and represented 484 months of follow-up. The 104 patients receiving primary durable devices had an actuarial survival of 90% at 6 mos. Competing risk analysis at 6 mos revealed 54% of pts transplanted, 37% alive on support, 8 % died and 1 % recovery. In the overall cohort, there were 8 early (&lt;1mo) and 5 late deaths. Reported serious adverse events included infection (42), bleeding (40), device malfunction (37) and neurologic dysfunction (33). CONCLUSIONS: Pedimacs constitutes the largest single data repository with detailed information of pediatric pts implanted with all types of VADs. Initial data show a higher rate of use of pulsatile devices as compared to contemporaneous adult data. Survival rates are excellent despite varying patient characteristics and pump types. With further data collection, analysis of patient risk factors critical to improving outcomes will be possible.
AN EPIDEMIC OF HISTOPLASMOSIS INVOLVING MAN AND ANIMALS
Authors: M L FURCOLOW, R W MENGES, H W LARSH
Journal: Annals of Internal Medicine (1955)

Article1 July 1955AN EPIDEMIC OF HISTOPLASMOSIS INVOLVING MAN AND ANIMALSM. L. FURCOLOW, M.D., R. W. MENGES, D.V.M., H. W. LARSH, Ph.D.M. L. FURCOLOW, M.D., R. W. MENGES, D.V.M., H. W. LARSH, Ph.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-43-1-173 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAlthough the characteristics of 13 epidemics of histoplasmosis have been described by Furcolow and Grayston,1, 2 the present epidemic represents one in which complete studies were done not only of the human cases but also of the animals and, in particular, the environment from which the infection was acquired. From the site of this epidemic the first isolation of Histoplasma capsulatum from the air was made.3This epidemic occurred on a farm near Atcheson, Kansas, and involved a mother, father, their two sons, and the brother of the father. The medical histories of each case will be described and x-rays...Bibliography1. FurcolowGrayston MLJT: Occurrence of histoplasmosis in epidemics—etiologic studies, Am. Rev. Tuber. 68: 307-320 (Sept.) 1953. MedlineGoogle Scholar2. GraystonFurcolow JTML: The occurrence of histoplasmosis in epidemics—epidemiological studies, Am. J. Pub. Health 43: 665-676 (June) 1953. CrossrefGoogle Scholar3. IbachLarshFurcolow MJHWML: Epidemic histoplasmosis and airborne Histoplasma capsulatum , Proc. Soc. Exper. Biol. and Med. 85: 72-74, 1954. CrossrefMedlineGoogle Scholar4. MengesFurcolowHabermann RWMLRT: An outbreak of histoplasmosis involving animals and man, Am. J. Vet. Research 15: 520-524 (Oct.) 1954. MedlineGoogle Scholar5. ZeidbergAjello LDL: Environmental factors influencing the occurrence of Histoplasma capsulatum and Microsporum gypseum in soil, J. Bact. 68: 156-159 (Aug.) 1954. CrossrefMedlineGoogle Scholar6. Larsh HW: Natural reservoirs of the fungus, presented at Histoplasmosis Conference, Excelsior Springs, Missouri, November 18, 1952. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Kansas City, Kansas*Received for publication January 7, 1955.From the Communicable Disease Center, Public Health Service, U. S. Department of Health, Education, and Welfare. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByMicrobiology of the built environmentAcute Histoplasmosis Presenting as the Adult Respiratory Distress SyndromeDie HistoplasmoseHyperthermia, Fever and Infectious DiseasesPulmonary histoplasmosisImmunbiologisch-serologische Nachweisverfahren bei PilzerkrankungenHistoplasmosisEpidemic histoplasmosisHISTOPLASMOSIS IN THE AGED†Histoplasmosis: Recent DevelopmentsEpidemiology of histoplasmosis 1 July 1955Volume 43, Issue 1Page: 173-181KeywordsHistoplasma capsulatumHistoplasmosisMedical servicesPneumonitisThorax Issue Published: 1 July 1955 PDF DownloadLoading ...
Fabricated or induced illness in children
Authors: R. G Wilson
Journal: BMJ (2001)

In 1970 the Department of Health issued a small orange booklet, The Battered Baby . For 25 years the association of fractures and subdural haematoma with wilful violence had been known, but Kempe had coined this emotive title only eight years before. That form of abuse is now only part of the whole range of harm to children that society has recognised. Last month the Department of Health continued the story by issuing multidisciplinary guidance on fabricated or induced illness in children.

Significant harm to children such as smothering or poisoning which simulated illness and which involved and deceived doctors has been known for at least 40 years. It took the honesty of Roy Meadow to describe his personal experience and his journalistic flair to label it “Munchausen by proxy” in 1977.1 His article drew the world's attention to fabricated or induced illness and led to more accounts, to reviews,2 and to research—though research has not been helped by arguments about what is or is not Munchausen by proxy.3

Even today one has to state clearly that some carers, including parents, do harm children, and that they sometimes involve health professionals in doing so. Doctors and others may not only fail to understand the origins of …
Abstract 17568: Arrhythmogenic Myocardial Remodeling in Adults with Surgically Corrected Tetralogy of Fallot
Authors: Heiko Schneider, Oliver Monfredi, Lucy Murfitt, Hayley Bennett, Ian P Temple, David Knight, Ronan O’Cualain, Halina Dobrzynski, Julian Selley, Parveen Sharma, George Hart, Ashraf Kitmitto, Andreas J Hoschtitzky, Mark R Boyett, Vaikom S Mahadevan
Journal: Circulation (2014)

Introduction: Adults after repair of Tetralogy of Fallot (ToF) have an increased risk of heart failure, arrhythmias and sudden death.

We hypothesize that electrophysiological remodeling of the right atrium (RA), right ventricle (RV) and right ventricular outflow tract (RVOT) is responsible.

Methods: We collected RA, RV and RVOT biopsies from 10 ToF patients (6 male) at the time of pulmonary valve replacement. Biopsies were also taken from 9 control patients (4 male) with left ventricular outflow tract obstruction without evidence of septal defects, previous arrhythmia or right-sided heart disease. We performed: (i) extracellular matrix (ECM) quantification; (ii) RT-qPCR to quantify mRNA for ion channels, transporters, connexins, inflammatory markers and ECM constituents; (iii) proteomics (liquid chromatography and mass spectrometry (MS)) on 6 patients per group to quantify ~1600 proteins; and (iv) Western Blot for selected proteins.

Results: Mean age at surgery was 32±4 and 22±2 years in the ToF and control groups respectively. There were significant changes in the relative abundance of mRNAs for ion channels, adrenergic receptors, ECM, and heart failure markers (ANP and BNP) in ToF patients compared with controls. MS highlighted over 300 significant differences, specifically changes in proteoglycans and downregulation of mitochondrial respiratory complexes 1 and 3 in ToF patients compared with controls. No significant difference in fibrosis on histological analysis between the two groups was seen. A selection of changes is displayed in Table 1.

Conclusion: The RA and RVOT undergo significant remodeling in ToF. Changes in ion channels, transporters and Ca2+-handling (especially SERCA2A, RYR2, Calsequestrin) as well as gap junction proteins (Cx43) are likely to alter ionic currents, with increased arrhythmia risk. This remodeling is similar to changes in heart failure and ischemia-reperfusion and may contribute to the arrhythmias seen in ToF.

   ![][1]  [1]: /embed/graphic-1.gif
ADHD Often Undiagnosed in Adults: Appropriate Treatment May Benefit Work, Family, Social Life
Authors: L. Lamberg
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Predicting performance of cough reflex sensitivity, exhaled nitric oxide (eNO) and bronchial responsiveness for efficacy of bronchodilator therapy on isolated chronic non-productive cough
Authors: Masaki Fujimura, Noriyuki Ohkura, Akira Tokuda, Yuko Waseda
Journal: European Respiratory Journal (2011)

Background:  Chronic cough responding to bronchodilator therapy (BDT) was originally reported as cough variant asthma (CVA), in which bronchial responsiveness was shown to be mildly increased. Our aim was to elucidate whether cough reflex sensitivity, exhaled nitric oxide (eNO) and bronchial responsiveness could predict efficacy of BDT on chronic non-productive cough.   Methods:  Consecutive patients with non-productive cough lasting at least 8 weeks who visited our respiratory medicine clinic from 2005 to 2010 and gave informed consent for participating in this study were enrolled. Exhaled NO, capsaicin cough sensitivity (C5) and bronchial reversibility were measured in this order at their first visit. Bronchial responsiveness (PC20) was measured at their second visit following 6-day BDT.   Results:  The study protocol was fully completed in 117 patients. Multivariate regression analysis revealed that only C5 was significantly (r=0.430, p   Conclusions:  Measurement of C5 may be useful for predicting efficacy of BDT on chronic non-productive cough, in other words for diagnosis of CVA.
Risk of Contact Vaccinia From Immunization Sites—Reply
Authors: Vinaya Garde, David Harper, Mary P. Fairchok
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Further Insight Into the Cardiovascular Risk Calculator
Authors: Michael Soljak, Azeem Majeed
Journal: JAMA Internal Medicine (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Gαq/Gα11 in cardiomyocytes
Authors: Nina Wettschureck, Hartmut Rütten, Alexandra Zywietz, Doris Gehring, Tom M. Wilkie, Ju Chen, Kenneth R. Chien, Stefan Offermanns
Journal: Nature Medicine (2001)
Clinical competence statement on carotid stenting: Training and credentialing for carotid stenting—multispecialty consensus recommendations
Authors: Kenneth Rosenfield, Joseph D. Babb, Christopher U. Cates, Michael J. Cowley, Ted Feldman, Anthony Gallagher, William Gray, Richard Green, Michael R. Jaff, K. Craig Kent, Kenneth Ouriel, Gary S. Roubin, Bonnie H. Weiner, Christopher J. White
Journal: Journal of the American College of Cardiology (2004)